[1] LOANE D J,FADEN A I.Neuroprotection for traumatic brain injury:translational challenges and emerging therapeutic strategies[J].Trends Pharmacol Sci,2010,31(12):596-604.
[2] RICO G,LEANDRO E,ROJAS S,et al.The effect of the monocyte locomotion inhibitory factor (MLIF) produced by Entamoeba histolytica upon nitric oxide production by human leukocytes[J].Arch Med Res,2000,31(4 Suppl):S90-S91.
[3] ZHANG Y F,CHEN J,LI F,et al.A pentapeptide monocyte locomotion inhibitory factor protects brain ischemia injury by targeting the eEF1A1/endothelial nitric oxide synthase pathway[J].Stroke,2012,43(10):2764-2773.
[4] 程浩,芮耀诚,章越凡,等.生物活性肽-单核细胞迁移抑制因子研究进展[J].药学实践杂志,2015,33(1):17-19,27.
[5] ZHU Q Z,ZHANG Y F,LIU Y L,et al.MLIF alleviates SH-SY5Y neuroblastoma injury induced by oxygen-glucose deprivation by targeting eukaryotic translation elongation factor 1A2[J].PLoS One,2016,11(2):e0149965.
[6] MCINTOSH T K,VINK R,NOBLE L,et al.Traumatic brain injury in the rat:characterization of a lateral fluid-percussion model[J].Neuroscience,1989,28(1):233-244.
[7] MARKLUND N,HILLERED L.Animal modelling of traumatic brain injury in preclinical drug development:where do we go from here?[J].Br J Pharmacol,2011,164(4):1207-1229.
[8] FUKUDA A M,BADAUT J.Aquaporin 4:a player in cerebral edema and neuroinflammation[J].J Neuroinflammation,2012,9:279.
[9] MARMAROU A.Pathophysiology of traumatic brain edema:current concepts[J].Acta Neurochir Suppl,2003,86:7-10.
[10] FEICKERT H J,DROMMER S,HEYER R.Severe head injury in children:impact of risk factors on outcome[J].J Trauma,1999,47(1):33-38.
[11] DONKIN J J,VINK R.Mechanisms of cerebral edema in traumatic brain injury:therapeutic developments[J].Curr Opin Neurol,2010,23(3):293-299.
[12] HALL E D,VAISHNAV R A,MUSTAFA A G.Antioxidant therapies for traumatic brain injury[J].Neurotherapeutics,2010,7(1):51-61.
[13] JI X T,LIU W B,XIE K L,et al.Beneficial effects of hydrogen gas in a rat model of traumatic brain injury via reducing oxidative stress[J].Brain Res,2010,1354:196-205.